Menu

Sequester Hits Research Centers

Academic research universities and cancer centers will have a large hunk of their funding cut because of the government sequester.

Apr 7, 2013
Edyta Zielinska

FLICKR, TAX CREDITSHarvard University, Johns Hopkins University, the University of Pennsylvania, and Washington University in St. Louis will be a few of the casualties of the government budget sequester that was initiated last month after Congress was unable agree on a plan to reduce the federal deficit. The 5 percent budget cut to the National Institutes of Health will likely affect these institutions, which expect to lose tens of millions in federal funding over the next 8 months.

“Of all the blinkered buzz-saw cuts in this year’s $85 billion spending sequestration, perhaps none is as counterproductive—or as flat-out boneheaded—as the one now hitting medical research,” wrote Howard Fineman an editor at the Huffington Post. Those cuts will not only prevent the institutions from generating new technology and new jobs, but slow the efforts to attract top researchers and entrepreneurs, Fineman argued.

Cancer centers that have relied on Medicare funding to provide expensive chemotherapeutics to patients are also being hit hard by the sequester, and some have already begun to turn patients away.  “If we treated the patients receiving the most expensive drugs, we’d be out of business in 6 months to a year,” Jeff Vacirca, chief executive of North Shore Hematology Oncology Associates in New York, told The Washington Post. After an emergency meeting last month (March 26), Vacirca’s small private clinics—which have been disproportionately hit by the cuts—decided to stop seeing a third of their 16,000 Medicare patients.

(Hat tip to GenomeWeb)

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!